Yungjin Pharm to market HEXAL’s Amlocard tablet

Published: 2004-10-07 06:21:00
Updated: 2004-10-07 06:21:00
Yungjin Pharm said on October 4 it has obtained exclusive marketing and distribution rights to HEXAL’s Amlocard (amlodipine besylate) tablet for the treatment of hypertension in Korea.

Amlocard tablet, which was approved in 15 European countries including Germany, Denmark and Austria, has been...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.